Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Human Resources Officer | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,250 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 6,250 · Balance 6,250 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.66 · Expires 2031-02-10 | Direct | 37,500 |
Reported balance
After 2021-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-11 · Grant · Acquired 37,500 · Balance 37,500 F3: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date
F3: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2021 Filed Feb 16, 2021 22:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-21-024417 · tm216849-5_4seq1.xml · derivative · entry 2 Kelner Simon · CIK 0001742917 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2031-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:28 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024417 · tm216849-5_4seq1.xml · derivative · entry 1 Kelner Simon · CIK 0001742917 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080536 · a4.xml · derivative · entry 1 Kelner Simon · CIK 0001742917 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:24 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $17.87 | $0.00 |
DisclosureSEC source: 0001104659-20-022828 · a4.xml · derivative · entry 1 Kelner Simon · CIK 0001742917 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009039 · a4.xml · derivative · entry 1 Kelner Simon · CIK 0001742917 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $34.89 | $0.00 |
DisclosureSEC source: 0001104659-18-039182 · a4.xml · derivative · entry 1 Kelner Simon · CIK 0001742917 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The option vests as follows: (1) 25% on June 4, 2019, and (2) the remaining 75% in 12 equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.